Like many biotechs, Arena Pharmaceuticals, Inc. (NASDAQ: ARIA) hasn’t had a great year in 2016, so far. Shares of the biopharmaceutical company are down more than 20% year to date.
Arena announced its third-quarter results after the market closed on Monday. Were there signs that the year might finish better than it started? Here’s what you need to know about Arena’s results.
